Worni Mathias, Akushevich Igor, Greenup Rachel, Sarma Deba, Ryser Marc D, Myers Evan R, Hwang E Shelley
Division of Advanced Oncologic and GI Surgery, Department of Surgery, (MW, RG, DS, ESH), Center for Population Health and Aging (IA), Department of Obstetrics and Gynecology (ERM), and Department of Mathematics (MDR), Duke University Medical Center, Durham NC; Department of Visceral Surgery and Medicine, Inselspital, Berne University Hospital and University of Berne, Berne, Switzerland (MW).
J Natl Cancer Inst. 2015 Sep 30;107(12):djv263. doi: 10.1093/jnci/djv263. Print 2015 Dec.
Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS).
The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were performed using inverse probability weights (IPW)-adjusted competing risk analyses for DSS and Cox proportional hazard regression for OS. All tests performed were two-sided.
One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone (HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%).
We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.
早期乳腺癌(导管原位癌[DCIS])的当代治疗对长期预后的影响仍未明确界定。我们旨在评估DCIS的全国治疗趋势,并确定其对疾病特异性生存率(DSS)和总生存率(OS)的影响。
查询监测、流行病学和最终结果(SEER)登记处1991年至2010年诊断为DCIS的患者。使用 Cochr an - Armitage趋势检验分析治疗模式趋势。采用逆概率加权(IPW)调整的竞争风险分析评估DSS,采用Cox比例风险回归分析评估OS。所有检验均为双侧检验。
共识别出121080例DCIS患者。接受乳房肿瘤切除术加放射治疗的患者比例最高(43.0%),其次是单纯乳房肿瘤切除术(26.5%)以及单侧(23.8%)或双侧乳房切除术(4.5%),且随着时间推移有显著变化。前哨淋巴结活检率在乳房切除术中从9.7%增至67.1%,在乳房肿瘤切除术中从1.4%增至17.8%。与乳房切除术相比,乳房肿瘤切除术加放射治疗的OS更高(风险比[HR]=0.79,95%置信区间[CI]=0.76至0.83,P<.001),单纯乳房肿瘤切除术的OS更低(HR = 1.17,95% CI = 1.13至1.23,P<.001)。IPW调整后的十年DSS在乳房肿瘤切除术加放疗中最高(98.9%),其次是乳房切除术(98.5%)和单纯乳房肿瘤切除术(98.4%)。
我们发现1991年至2010年DCIS的治疗模式有显著变化。比较局部区域治疗方案的预后时,我们观察到OS的差异大于DSS,这可能既反映了普遍存在的患者选择偏倚,也反映了两组之间乳腺癌预后在临床上可忽略不计的差异。